Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. decreased its position in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTLGet Rating) by 1.1% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 58,619 shares of the company’s stock after selling 645 shares during the quarter. Russell Investments Group Ltd. owned 0.13% of Zentalis Pharmaceuticals worth $2,703,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. DekaBank Deutsche Girozentrale lifted its holdings in Zentalis Pharmaceuticals by 2.6% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 13,650 shares of the company’s stock valued at $1,139,000 after acquiring an additional 350 shares during the period. HighTower Advisors LLC lifted its holdings in Zentalis Pharmaceuticals by 1.2% in the fourth quarter. HighTower Advisors LLC now owns 30,262 shares of the company’s stock valued at $2,544,000 after acquiring an additional 357 shares during the period. Arizona State Retirement System raised its stake in shares of Zentalis Pharmaceuticals by 7.7% during the 4th quarter. Arizona State Retirement System now owns 6,063 shares of the company’s stock worth $510,000 after buying an additional 436 shares during the period. State Board of Administration of Florida Retirement System raised its stake in shares of Zentalis Pharmaceuticals by 5.5% during the 4th quarter. State Board of Administration of Florida Retirement System now owns 10,949 shares of the company’s stock worth $920,000 after buying an additional 571 shares during the period. Finally, SG Americas Securities LLC raised its stake in shares of Zentalis Pharmaceuticals by 4.1% during the 4th quarter. SG Americas Securities LLC now owns 19,484 shares of the company’s stock worth $1,638,000 after buying an additional 773 shares during the period. Institutional investors and hedge funds own 95.01% of the company’s stock.

Insider Buying and Selling at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, COO Kevin D. Bunker sold 1,710 shares of the stock in a transaction dated Wednesday, July 13th. The stock was sold at an average price of $30.02, for a total value of $51,334.20. Following the sale, the chief operating officer now owns 108,290 shares of the company’s stock, valued at approximately $3,250,865.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, COO Kevin D. Bunker sold 5,000 shares of the stock in a transaction dated Wednesday, July 20th. The stock was sold at an average price of $30.00, for a total value of $150,000.00. Following the transaction, the chief operating officer now owns 100,000 shares in the company, valued at approximately $3,000,000. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Kevin D. Bunker sold 1,710 shares of the stock in a transaction dated Wednesday, July 13th. The shares were sold at an average price of $30.02, for a total value of $51,334.20. Following the completion of the transaction, the chief operating officer now owns 108,290 shares in the company, valued at approximately $3,250,865.80. The disclosure for this sale can be found here. Insiders have sold 31,710 shares of company stock valued at $953,084 in the last quarter. Corporate insiders own 19.90% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. HC Wainwright reduced their target price on Zentalis Pharmaceuticals from $120.00 to $55.00 and set a “buy” rating for the company in a research note on Wednesday. Cowen started coverage on Zentalis Pharmaceuticals in a research report on Tuesday, July 12th. They set an “outperform” rating for the company. SVB Leerink dropped their price target on Zentalis Pharmaceuticals from $67.00 to $42.00 and set an “outperform” rating for the company in a research report on Wednesday. Guggenheim dropped their price target on Zentalis Pharmaceuticals to $57.00 and set a “na” rating for the company in a research report on Tuesday, May 17th. Finally, Wedbush dropped their price target on Zentalis Pharmaceuticals from $71.00 to $51.00 and set an “outperform” rating for the company in a research report on Tuesday, May 10th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $61.38.

Zentalis Pharmaceuticals Price Performance

ZNTL stock opened at $28.51 on Friday. The firm has a market capitalization of $1.62 billion, a P/E ratio of -7.41 and a beta of 1.88. The business’s 50-day moving average is $27.84 and its two-hundred day moving average is $34.62. Zentalis Pharmaceuticals, Inc. has a 1 year low of $17.33 and a 1 year high of $87.19.

About Zentalis Pharmaceuticals

(Get Rating)

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.

Featured Stories



Receive News & Ratings for Zentalis Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.